---
title: "Causal-RSV: Real-World Causal Analysis of RSVpreF Vaccine Effectiveness in Infants with Co-availab"
id: "medrxiv-17-causal-rsv-causal-analysis-of-rsv-vaccine-effects-in-infants-using-real-world"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-17-causal-rsv-causal-analysis-of-rsv-vaccine-effects-in-infants-using-real-world"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.07.16.26356876v1?rss=1"
published_at: "2026-07-18T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Causal-RSV: Real-World Causal Analysis of RSVpreF Vaccine Effectiveness in Infants with Co-availab
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-17-causal-rsv-causal-analysis-of-rsv-vaccine-effects-in-infants-using-real-world
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.07.16.26356876v1?rss=1)
- **Published At:** 2026-07-18T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The preprint describes the CAUSAL-RSV protocol to estimate real-world effectiveness of the maternal prefusion F protein subunit vaccine (**RSVpreF**) against severe infant respiratory syncytial virus (**RSV**) outcomes when both maternal vaccination and infant monoclonal antibody (**mAb**) prophylaxis are available. - The investigators will use a national longitudinal cohort of mother–infant dyads drawn from the Optum Labs Data Warehouse (OLDW) spanning the 2023–24, 2024–25, and 2025–26 RSV seasons. - The study applies **causal mediation analysis** to partition vaccine effects, treating receipt of infant **long-acting mAb** as a mediating variable to estimate the total effect of maternal vaccination within a hybrid prevention program. - The protocol emphasizes assessment of post-licensure, real-world programmatic effectiveness rather than randomized efficacy; no trial results or effectiveness estimates are reported in the preprint. - Ethical review: the UCLA IRB determined the protocol does not constitute human subjects research under DHHS and FDA definitions (IRB-25-2622), so formal IRB approval was not required. - Funding was declared from the National Institute of Allergy and Infectious Diseases (NIAID), R21AI191038. - Competing interests are disclosed for several authors, including roles on DSMBs, consulting, and prior investigator roles with multiple vaccine manufacturers; other authors reported no conflicts. - The document is a medRxiv preprint posted July 18, 2026, and has not been peer reviewed; authors caution it should not guide clinical practice pending evaluation. - The preprint states that results will inform understanding of the **total effect** of maternal RSVpreF vaccination when used alongside infant mAb in routine care, but specific methods, statistical models, or outcome definitions beyond the mediation framework are not fully detailed in the abstract.
## Clinical Analysis & Structured Key Points
Skip to main content HOMESUBMITFAQBLOGALERTS / RSSRESOURCESABOUT Search for this keyword Advanced Search Follow this preprint CAUSAL-RSV: Causal Analysis of RSV Vaccine Effects in Infants Using Real-World Data View ORCID Profile Annette K Regan, View ORCID Profile Matthew M Coates, View ORCID Profile Sheena G Sullivan, View ORCID Profile Flor M Munoz, View ORCID Profile Stacey L Rowe, View ORCID Profile Chantal Avila, View ORCID Profile Onyebuchi A Arah doi: https://doi.org/10.64898/2026.07.16.26356876 This article is a preprint and has not been certified by peer review [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice. AbstractInfo/HistoryMetrics Preview PDF Abstract Respiratory syncytial virus (RSV) contributes to substantial morbidity and mortality in young children each year. In 2023, two new prevention products were licensed and recommended in the United States (US), including a prefusion F protein subunit vaccine (RSVpreF) administered during pregnancy and a long-acting monoclonal antibody (mAb) administered in infants. Although post-licensure real-world studies support the effectiveness of RSVpreF vaccine during pregnancy, existing studies have been conducted in settings where only RSVpreF vaccine is available. The real-world effectiveness of RSVpreF vaccine in settings where both RSVpreF vaccine and mAbs are available is not yet well understood. The goal of this study is to estimate the real-world effectiveness of the RSVpreF vaccine against severe infant RSV by applying causal mediation analysis with receipt of mAbs as a mediating variable. Using a national cohort of mother-infant dyads with the Optum Labs Data Warehouse (OLDW), we will model vaccine and mAb effects in a longitudinal cohort spanning the 2023-24, 2024-25, and 2025-26 RSV seasons. Results will be used to better understand the total effect of RSVpreF vaccination when it is used as one component within a hybrid infant RSV prevention program. Competing Interest Statement Annette K. Regan reports membership on a data safety monitoring board (DSMB) for matters unrelated to the presented research, consulting fees for unrelated research from the Pan American Health Organization, and unrelated research funding paid to her institution from Merck Sharp & Dohme, Pfizer, and Bavarian Nordic. Sheena G. Sullivan reports consulting for Astra-Zeneca, GSK, Sanofi, Pfizer, Moderna, CSL Seqirus, Novavax, and Evo Health on work unrelated to the presented research. Flor M. Munoz has been an investigator in pediatric studies of coronavirus disease 2019 vaccines for Pfizer and Moderna, and for a pediatric remdesivir study conducted by Gilead Sciences; is an investigator on projects supported by the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC); has served as a member of the DSMB for clinical trials conducted by Pfizer, Dynavax, Moderna, Meissa Vaccines, Virometix, and the NIH; and has served as a consultant to Merck, Moderna, Sanofi, Astra Zeneca, and GSK. Stacey L. Rowe reports consulting for CSL Seqirus on work unrelated to the presented research. The other authors do not report any potential conflicts of interest. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: This protocol was reviewed by the Institutional Review Board of the University of California Los Angeles and determined to not involve research with human subjects as defined by the Department of Health & Human Services (DHHS) and Food and Drug Administration (FDA) regulations. IRB review and approval was therefore not required (IRB-25-2622). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes FUNDER INFORMATION DECLARED National Institute of Allergy and Infectious Diseases, https://ror.org/043z4tv69, R21AI191038 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license. bioRxiv and medRxiv thank the following for their generous financial support: The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. Donate to openRxiv Back to top Previous Next Posted July 18, 2026. Download PDF Print/Save Options Author Declarations Supplementary Material Data/Code Email Share Citation Tools Get QR code Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos Subject Areas All Articles Addiction Medicine Allergy and Immunology Anesthesia Cardiovascular Medicine Dentistry and Oral Medicine Dermatology Emergency Medicine Endocrinology (including Diabetes Mellitus and Metabolic Disease) Epidemiology Forensic Medicine Gastroenterology Genetic and Genomic Medicine Geriatric Medicine Health Economics Health Informatics Health Policy Health Systems and Quality Improvement Hematology HIV/AIDS Infectious Diseases (except HIV/AIDS) Intensive Care and Critical Care Medicine Medical Education Medical Ethics Nephrology Neurology Nursing Nutrition Obstetrics and Gynecology Occupational and Environmental Health Oncology Ophthalmology Orthopedics Otolaryngology Pain Medicine Palliative Medicine Pathology Pediatrics Pharmacology and Therapeutics Primary Care Research Psychiatry and Clinical Psychology Public and Global Health Radiology and Imaging Rehabilitation Medicine and Physical Therapy Respiratory Medicine Rheumatology Sexual and Reproductive Health Sports Medicine Surgery Toxicology Transplantation Urology Evaluation/discussion of this paper x 0 0 0 0 0 0 We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. Continue Find out more
## Related Clinical Research

- [Bundibugyo Ebola outbreak reveals gaps in Ebola preparedness and need for pan-filovirus tools](https://medichelpline.com/clinical-feed/stat-news-1-opinion-we-prepared-for-ebola-but-not-this-ebola.md)
- [Ebola Preparedness: Addressing the Gap in Virus Species Research](https://medichelpline.com/clinical-feed/stat-news-9-opinion-we-prepared-for-ebola-but-not-this-ebola.md)
- [Phase 1 trials and PARTNERS platform target Bundibugyo Ebola strain](https://medichelpline.com/clinical-feed/medical-news-today-40-phase-1-trials-for-ebola-treatments-and-vaccines-offer-hope-say-experts.md)
- [Value of Entomological Monitoring and Active Adaptive Management for gHAT Vector Control](https://medichelpline.com/clinical-feed/medrxiv-9-can-non-routine-data-collection-help-decision-making-for-gambiense-sleeping.md)
- [Bundibugyo virus infection treated with MBP134 monoclonal antibodies and remdesivir: a case report](https://medichelpline.com/clinical-feed/nature-0-a-case-of-bundibugyo-virus-disease-treated-with-monoclonal-antibodies-and.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.